Symposium celebrates new Institute of Urologic Oncology at UCLA

UCLA Health article
This educational symposium celebrates the March 3 launch of the Institute of Urologic Oncology at UCLA — a new academic and clinical institute designed to bring together scientists and physicians dedicated to developing cutting-edge cancer therapies. The multidisciplinary team will help move treatments from the lab to the bedside quicker, offering patients the latest in personalized treatments for prostate, bladder, kidney and testicular cancers.

Advances in imaging, minimally invasive surgery and molecularly targeted drug therapies have led to more individualized treatments based on a patient's unique tumor biology, biochemistry and molecular signature. This one-day conference on personalized cancer therapies will feature speakers from leading cancer institutions across the country who will discuss the latest discoveries and trends in tailored cancer treatments.
Symposium participants will include:
Dr. Arie Belldegrun
Belldegrun, director of the Institute of Urologic Oncology at UCLA, will deliver the welcome address. (9 a.m.)
Dr. Jean B. DeKernion
Professor and chair of the UCLA Department of Urology
Judith C. Gasson
Director of UCLA's Jonsson Comprehensive Cancer Center
Dr. Gerald S. Levey
Vice chancellor for medical sciences and dean of the David Geffen School of Medicine at UCLA
Michael Milken
Milken, chairman of the Milken Institute, will survey the current state of medical research within the broader social and political environment in his keynote address. (10 a.m.) 
Dr. Andrew C. von Eschenbach
Former Food and Drug Administration commissioner and former director of the National Cancer Institute, will present his keynote address, "Government Programs for Cancer Prevention and Cure: Present and Future Progress." (10:30 a.m.)
Dr. Dennis J. Slamon
Slamon, professor and chief of the UCLA Division of Hematology and Oncology, whose laboratory and clinical research led to the development of the molecularly targeted breast cancer drug Herceptin, will discuss his work and the challenges of pursuing targeted therapies. (12:45 p.m.)
Dr. Philip Kantoff
Kantoff, director of the Lank Center for Genitourinary Oncology at the Dana Farber Cancer Institute and chief of the division of solid tumor oncology and professor of medicine at Harvard University School of Medicine, will discuss advances in personalized prostate cancer therapies. (1:15 p.m.)
Dr. W. Marston Linehan
Linehan, branch chief of urologic oncology at the National Institutes of Health's National Cancer Center, will present the latest targeted treatments in kidney cancer. (1:45 p.m.)
Dr. Colin P. Dinney
Dinney, professor and chair of the department of urology at the University Texas M.D. Anderson Cancer Center, will cover the newest bladder cancer therapies. (2:15 p.m.)
9 a.m. to 3 p.m., Tuesday, March 3
Dr. S. Jerome and Judith D. Tamkin Auditorium at Ronald Reagan UCLA Medical Center (B-Level),
757 Westwood Plaza (UCLA campus)
Rachel Champeau, UCLA Health Sciences Media Relations, 310-794-0777
Kim Irwin, UCLA's Jonsson Cancer Center, 310-206-2805
Press should call media contacts to reserve parking. Parking will be available in Lot 8 after picking up a pass from the parking kiosk on Westwood Boulevard.
Media Contact:
Rachel Champeau
(310) 794-2270
[email protected]

Related Content


Media Contact

Rachel Champeau
(310) 794-2270
[email protected]